Cleopatra Hospitals Group S.A.E.

CASE:CLHO Stock Report

Market Cap: ج.م10.0b

Cleopatra Hospitals GroupE Valuation

Is CLHO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CLHO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CLHO (EGP6.94) is trading above our estimate of fair value (EGP2.76)

Significantly Below Fair Value: CLHO is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLHO?

Other financial metrics that can be useful for relative valuation.

CLHO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3x
Enterprise Value/EBITDA13.3x
PEG Ratio1.3x

Price to Earnings Ratio vs Peers

How does CLHO's PE Ratio compare to its peers?

The above table shows the PE ratio for CLHO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.3x
NINH Nozha International Hospital
13.9xn/aج.م1.4b
ISPH Ibnsina Pharma
13.7x33.9%ج.م2.7b
9906 Honliv Healthcare Management Group
36.6xn/aHK$1.5b
CMR Chiang Mai Ram Medical Business
33.2xn/a฿8.0b
CLHO Cleopatra Hospitals GroupE
31x23.5%ج.م10.0b

Price-To-Earnings vs Peers: CLHO is expensive based on its Price-To-Earnings Ratio (31x) compared to the peer average (24.3x).


Price to Earnings Ratio vs Industry

How does CLHO's PE Ratio compare vs other companies in the Global Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.7%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.7%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: CLHO is expensive based on its Price-To-Earnings Ratio (31x) compared to the Global Healthcare industry average (23.1x).


Price to Earnings Ratio vs Fair Ratio

What is CLHO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLHO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31x
Fair PE Ratio17.8x

Price-To-Earnings vs Fair Ratio: CLHO is expensive based on its Price-To-Earnings Ratio (31x) compared to the estimated Fair Price-To-Earnings Ratio (17.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CLHO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentج.م6.94
ج.م7.54
+8.6%
8.6%ج.م8.00ج.م6.62n/a3
May ’25ج.م6.12
ج.م7.54
+23.2%
8.6%ج.م8.00ج.م6.62n/a3
Apr ’25ج.م6.96
ج.م7.14
+2.6%
8.6%ج.م8.00ج.م6.62n/a3
Mar ’25ج.م6.03
ج.م7.14
+18.4%
8.6%ج.م8.00ج.م6.62n/a3
Feb ’25ج.م4.99
ج.م6.98
+39.9%
8.6%ج.م8.00ج.م6.50n/a4
Jan ’25ج.م4.72
ج.م6.06
+28.4%
11.7%ج.م6.62ج.م5.06n/a3
Dec ’24ج.م5.10
ج.م6.06
+18.8%
11.7%ج.م6.62ج.م5.06n/a3
Nov ’24ج.م4.23
ج.م6.06
+43.3%
11.7%ج.م6.62ج.م5.06n/a3
Oct ’24ج.م3.87
ج.م6.06
+56.6%
11.7%ج.م6.62ج.م5.06n/a3
Sep ’24ج.م3.84
ج.م6.17
+60.8%
13.1%ج.م6.96ج.م5.06n/a3
Aug ’24ج.م3.98
ج.م6.36
+59.7%
12.1%ج.م6.96ج.م5.06n/a4
Jul ’24ج.م4.45
ج.م6.38
+43.3%
11.5%ج.م6.96ج.م5.15n/a4
Jun ’24ج.م4.58
ج.م6.38
+39.3%
10.2%ج.م6.96ج.م5.15n/a5
May ’24ج.م4.50
ج.م6.38
+41.8%
10.2%ج.م6.96ج.م5.15ج.م6.125
Apr ’24ج.م4.41
ج.م6.25
+41.8%
10.7%ج.م6.96ج.م5.15ج.م6.964
Mar ’24ج.م5.30
ج.م6.22
+17.3%
11.8%ج.م6.96ج.م5.00ج.م6.034
Feb ’24ج.م5.62
ج.م6.22
+10.6%
11.8%ج.م6.96ج.م5.00ج.م4.994
Jan ’24ج.م5.32
ج.م6.22
+16.8%
11.8%ج.م6.96ج.م5.00ج.م4.724
Dec ’23ج.م4.40
ج.م6.15
+39.8%
11.6%ج.م6.96ج.م5.00ج.م5.104
Nov ’23ج.م4.19
ج.م6.07
+44.9%
13.3%ج.م6.96ج.م5.00ج.م4.233
Oct ’23ج.م3.88
ج.م6.07
+56.4%
13.3%ج.م6.96ج.م5.00ج.م3.873
Sep ’23ج.م3.89
ج.م6.55
+68.5%
4.4%ج.م6.96ج.م6.30ج.م3.843
Aug ’23ج.م4.19
ج.م6.55
+56.4%
4.4%ج.م6.96ج.م6.30ج.م3.983
Jul ’23ج.م4.70
ج.م6.55
+39.4%
4.4%ج.م6.96ج.م6.30ج.م4.453
Jun ’23ج.م5.23
ج.م6.39
+22.2%
5.9%ج.م6.96ج.م5.90ج.م4.584
May ’23ج.م5.50
ج.م6.19
+12.6%
6.8%ج.م6.96ج.م5.80ج.م4.505

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.